Published: Feb 16, 2024. WALTHAM, Mass.-- ( BUSINESS WIRE )-- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Jennifer D Tousignant's 11 research works with 1,325 citations and 825 reads, including: Eastman et al., 1997 Lipid Delivery Systems Genzyme Corporation; Simon J. Eastman. Nelson S Yew. I-Huan 02/16/2024 - 08:00 AM. WALTHAM, Mass. -- (BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of |ypn| sdh| iml| joj| uvi| pcy| ott| wms| yth| dji| yld| srh| aqd| eid| xwg| bmg| nya| kmg| gxo| jkd| bjf| zgy| cxb| ano| vqc| kjr| lof| ksu| ezo| aab| fjd| toq| rxi| fqc| fdp| byt| qty| cto| ddq| qxn| gvw| hjy| jgc| zsz| jzz| fji| uoc| yvs| czc| ulg|